Skip to content

Effect of External Counter Pulsation on Coronary Artery Disease

Effect of External Counter Pulsation on Coronary Artery Disease (ECP-CAD)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03075124
Acronym
ECP-CAD
Enrollment
380
Registered
2017-03-09
Start date
2018-06-08
Completion date
2019-06-30
Last updated
2017-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Stable Chronic Angina

Keywords

Coronary Artery Disease, external counter pulsation, major adverse cardiovascular events

Brief summary

Coronary artery disease (CAD) is prevalent worldwide and the leading cause of mortality of citizens, external counter pulsation (ECP) has been elucidated that it may release angina symptoms and improve the prognosis of CAD, however, no multi-center control clinical study has been reported for further recommendation. The aim of this study is to evaluate the effect of ECP on CAD. To address this assumption, investigators enroll participants with stable CAD and randomize them into control or ECP group, the ECP intervention will be carried out with a standard protocol which involves 35 one-hour sessions (5 days a week) for continuous 7 weeks, and the follow-up will last for 1 year. The primary endpoint is the 1-year composite cardiovascular events (CCE), secondary endpoints include frequency of angina pectoris, heart function, biomarkers of arteriosclerosis, exercise tolerance and endothelial function.

Detailed description

CAD is the leading cause of non-tumor mortality in most countries, ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole. Cumulative evidences demonstrate that ECP can improve life quality and release refractory angina which is not optimally controlled despite optimal medical management and coronary revascularization in patients with CAD, though the previous multi-center control trial (PROBE-EECP) had been designed, no result about the effect of ECP on the prognosis of CAD has been reported. Thus, this study is designed to enroll 380 participants with stable CAD after evaluation of frequency of angina pectoris, heart function, biomarkers of arteriosclerosis, exercise tolerance and endothelial function, participants will be randomized into ECP intervention group or control group. All participants receive Guideline-driven standard medical treatment, ECP will be carried out with a standard protocol which involves 35 one-hour sessions (5 days a week) for continuous 7 weeks. Up to the end of ECP intervention, CCE will be follow up to 1 year, meanwhile, items as above will be retested for comparison.

Interventions

DEVICEExternal Counter Pulsation

A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.

Sponsors

Second Affiliated Hospital of Xi'an Jiaotong University
CollaboratorOTHER
Second Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Shanghai 10th People's Hospital
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
Eighth Affiliated Hospital, Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of coronary artery disease; * Signed informed consent.

Exclusion criteria

* Obvious aortic insufficiency; * Aortic aneurysm; * Aortic dissection; * Coronary fistula or severe coronary aneurysm; * Symptomatic Congestive heart failure; * Valvular heart disease; * Congenital heart diseases; * Cardiomyopathies * Cerebral hemorrhage within six months; * Uncontrolled hypertension, defined as SBP≥180mmHg or DBP≥110mmHg; * Lower limb infection; * Deep venous thrombosis; * Progressive malignancies

Design outcomes

Primary

MeasureTime frameDescription
composite cardiovascular events (CCE)Change from Baseline at 1-yearSudden cardiac death, angina pectoris after infarction, recurrent myocardial infarction;rehospitalization rate

Secondary

MeasureTime frameDescription
Frequency of angina pectoris per weekChange from Baseline frequency at 1 yearFrequency of angina pectoris
Dosage of Nitroglycerin use per weekChange from Baseline frequency and dosage at 1 yeartotal dosage of nitroglycerin
6-minute walking distanceChange from Baseline distance at 1 year6-minute walking distance

Countries

China

Contacts

Primary ContactGuifu Wu, PhD
wuguifu@mail.sysu.edu.cn+8615989893111
Backup ContactJianhang Du, PhD
zsudjhang@163.com+8613652851566

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026